# BARDA Seeks New Vaccine Platforms

BARDA has issued a draft Request for Project Proposals through the Rapid Response Partnership Vehicle (RRPV) for its New Vaccine Platforms program, anticipating approximately $160 million for up to six initial awards. Offerors are expected to demonstrate vaccine platforms against at least two specified infectious-disease targets, with work expected to begin in FY2027. The tentatively scheduled September 28, 2026 teaming event date has passed; the signal does not confirm whether it took place.

- Companies can use the draft RPP to assess whether their platforms can address at least two target diseases and prepare for the formal solicitation.
- The anticipated funding and up to six awards signal a multi-award opportunity for platform developers and prospective teaming partners.
- The signal directs prospective offerors to RRPV for formal solicitation and proposers-conference details; the event date should not be treated as upcoming.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** October 20, 2026

### Government Entities
- Biomedical Advanced Research and Development Authority (BARDA)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- U.S. Food and Drug Administration (FDA)

### Sources
- [1/2 a mini 🧵🪡

Highlight from my previous thread: https://t.co/UnrtekXZ5x
5/ 💉Unified Oversight of Next-Generation Platforms: 
Historically, NIAID at Bethesda handled early-stage basic research, while BARDA stepped in later to fund advanced development, manufacturing, and proc](https://x.com/missyTHX1138/status/2112637377193603462) - twitter-fed-procurement